With 340B Hospital Recertification Set to Begin Soon, HRSA To Host Webinar Aug. 11

Annual recertification of hospital eligibility for 340B drug discounts begins on Aug. 16.

The recertification period for hospitals to continue to participate in the 340B program begins in mid-August. The U.S. Health Resources Services Administration (HRSA) has scheduled an informational webinar on Wednesday, Aug. 11 at 1 p.m. Eastern time to discuss the

Read More »

Providers Support, Eli Lilly Opposes, Rescinding Trump’s 340B Health Center Insulin Rule

Drug manufacturer Eli Lilly told HRSA is opposes rescinding a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients.

340B trade associations and covered entities submitted public comments overwhelmingly supporting the Biden administration’s proposal to rescind a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients.

Drug manufacturer Eli Lilly,

Read More »

Rosen Introduces Bill to Boost Nonprofit Drug Makers’ Competitiveness

U.S. Sen. Jacky Rosen's (D-Nev.) bill, S. 2257, is aimed at boosting nonprofit drug companies' competitiveness.

U.S. Sen. Jacky Rosen (D-Nev.) has introduced legislation to help nonprofit drug companies compete in the market with their for-profit counterparts.

Rosen’s bill S. 2257, the Expanding Access to Affordable Prescription Drugs and Medical Devices Act, would make it simpler

Read More »

Hospital Groups Outraged at Boehringer Ingelheim, Company Defends Its Plans and Calls for 340B Overhaul

Hospitals call Boehringer Ingelheim’s contract pharmacy plans “appalling” while company calls for “substantial reform” of the 340B program.

Hospital trade group 340B Health has asked pharmaceutical giant Boehringer Ingelheim (BI) to withdraw its plan to cut off discounts for drugs that are distributed by contract pharmacies. However, BI does not appear to be backing down and the German-based company

Read More »

In Taking Up 340B Case, Supreme Court Could Reverse Longstanding Legal Doctrine

340B hospital challenge to Medicare Part B reimbursement could reverse long-standing legal doctrine.

The U.S. Supreme Court’s decision to take up a case involving steep Medicare Part B payment cuts to 340B hospital-operated outpatient sites took many legal experts by surprise. However, attorneys that 340B Report conferred with believe the court will be

Read More »

Hospitals File New Suit To Reverse Steep Part B Payment Cuts for 340B Drugs

More than 150 hospitals have sued HHS to reverse CMS's steep payment cut for 340B-purchased drugs covered under Medicare Part B. | Shutterstock

More than 150 hospitals have sued the U.S. Department of Health and Human Services (HHS) in the latest attempt by providers to end steep cuts in 340B reimbursement at their off-campus outpatient sites.

Filed in district court in Washington, D.C.,

Read More »

CMS Taps Massachusetts Medicaid Director to Run Key Post Impacting 340B Program

Massachusetts Medicaid director Daniel Tsai has been named Director of CMS’s Center for Medicaid and CHIP Services.

The U.S. Centers for Medicare & Medicaid Services (CMS) announced on Monday that Massachusetts’ Medicaid director Daniel Tsai has been named Deputy Administrator of CMS and Director of CMS’s Center for Medicaid and CHIP Services (CMCS). A record 80 million

Read More »

Recent Supreme Court Ruling Frees States to Stop PBMs’ 340B Two-Tier Pricing, Health Care Lawyers Say

A recent Supreme Court decision was a big win for 340B providers, K&L Gates partners (left to right) Don Walker, Leah D’Aurora Richardson, and Victoria Hamscho say in a new American Health Law Association paper.

A recent U.S. Supreme Court decision is spurring more states to enact laws banning pharmacy benefit managers (PBMs) from reimbursing 340B pharmacies less for prescription drugs than non-340B providers, health care lawyers say in a new paper.

According to the

Read More »

DOJ Asks Judge to Toss PhRMA Suit Against 340B Dispute Resolution System and Audit Guidelines

The federal government has asked a judge to dismiss PhRMA's legal challenge to the 340B administrative dispute resolution final rule and guidelines governing drug manufacturer audits of 340B covered entities.

The U.S. Justice Department (DOJ) has submitted a blistering motion asking that a lawsuit filed by Pharmaceutical Research and Manufacturers of America (PhRMA) to strike down the new 340B program administrative dispute resolution (ADR) process be tossed out of court.

Read More »

AHA Wants Express Scripts to End 340B Claims ID Policy Immediately

The American Hospital Association asked Express Scripts this week to immediately withdraw its new 340B claims identification requirement for covered entities and their contract pharmacies.

The American Hospital Association (AHA) told pharmacy benefit manager Express Scripts (ESI) this week its new 340B claims identification requirement for covered entities and their contract pharmacies “is a major overreach” and should be withdrawn immediately.

An ESI spokesperson was

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report